However, PD‐1 antibody‐based treatments for CRC are limited and only considered suitable in approximately 6% of cases (i.e., MSI‐H positive patients), since the majority of patients, especially those with solid tumors, show no response to anti‐PD‐1 or anti–PD‐L1 therapies.36, 37. Here, CD274 is linked to colorectal carcinoma.